Thoratec Corp.’s continued rapid growth is driven by implants of HeartMate II left-ventricular assist device in heart failure patients ineligible for a transplant.
During its Feb. 5 fourth-quarter earnings call, Thoratec CFO Gerhard Burbach explained that LVAD implants in transplant-ineligible patients – known...